Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites
This article was originally published in PharmAsia News
Executive Summary
Despite ongoing compliance probes, decelerating growth and continuing price pressure, Merck KGAA and Johnson & Johnson unveil bold localization plans in China with a fresh investment worth millions. They see the need to support essential drug supply, introduce new products and accelerate product registration in China.
You may also be interested in...
Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell
Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.